Key result
Adriamycin-induced cardiotoxicity manifests as structural and functional myocardial cell damage leading to severe HF.
Why the study?
Adriamycin cardiotoxicity causes myocardial structural and functional damage that can lead to severe cardiovascular diseases like heart failure, necessitating a synthesis of pathological mechanisms and animal models.
Design
Review
Answers are grounded in this paper and cite their sources.
Informs HF surveillance in adriamycin-treated patients; extends understanding of mechanisms, drugs, and animal models for future research.
Adriamycin is an anthracycline chemotherapy drug used in cancer treatment,and its cardiotoxicity primarily manifests as structural and functional damage to myocardial cells,which can lead to severe cardiovascular diseases such as heart failure.This article reviews recent advances in adriamycin-induced myocardial injury,focusing on its pathological mechanisms,potential therapeutic drugs,and commonly used animal models,to provide a research basis and intervention strategies for developing effective treatments.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2026) studied this question. Adriamycin-induced cardiotoxicity primarily manifests as structural and functional damage to myocardial cells, which can lead to severe cardiovascular diseases such as heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: